Literature DB >> 17457717

The workings of the amyloid diseases.

Vittorio Bellotti1, Mario Nuvolone, Sofia Giorgetti, Laura Obici, Giovanni Palladini, Paola Russo, Francesca Lavatelli, Vittorio Perfetti, Giampaolo Merlini.   

Abstract

The amyloidoses constitute a large group of diseases caused by an alteration in the conformation and metabolism of several globular proteins which, under particular conditions, deposit in tissues as insoluble fibrillar aggregates. To date, at least 24 different proteins have been recognized as causative agents of amyloid diseases. Despite a high heterogeneity in amino acid sequence, three-dimensional structure, and biological function, all amyloidogenic proteins share a reduced folding stability, a strong propensity to acquire more than one conformation, and the capacity to form almost indistinguishable amyloid fibrils. In some cases, the generation of an aggregation-prone state can be triggered or enhanced by the occurrence of mutations, a proteolytic cleavage, or a seeding process. The interaction between the amyloidogenic precursor, some common components of amyloid deposits, and the extra-cellular environment also plays a role in fibrillogenesis and in particular in the organ tropism of amyloid deposition. The process of amyloid fibril formation exerts a cytotoxic effect, resulting in tissue damage and organ dysfunction. Prefibrillar aggregates are thought to have an active part in this process. Due to the pathogenic complexity of amyloid diseases, the integration of several therapeutic interventions involving different critical levels of the amyloidogenic cascade is envisaged.

Entities:  

Mesh:

Year:  2007        PMID: 17457717     DOI: 10.1080/07853890701206887

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  16 in total

Review 1.  Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders.

Authors:  F Rahimi; A Shanmugam; G Bitan
Journal:  Curr Alzheimer Res       Date:  2008-06       Impact factor: 3.498

Review 2.  Assay strategies for identification of therapeutic leads that target protein trafficking.

Authors:  P Michael Conn; Timothy P Spicer; Louis Scampavia; Jo Ann Janovick
Journal:  Trends Pharmacol Sci       Date:  2015-06-08       Impact factor: 14.819

Review 3.  Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

4.  Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body 18F-Florbetapir PET/CT.

Authors:  Eric C Ehman; M Samir El-Sady; Marie F Kijewski; Yiu Ming Khor; Sophia Jacob; Frederick L Ruberg; Vaishali Sanchorawala; Heather Landau; Andrew J Yee; Giada Bianchi; Marcelo F Di Carli; Rodney H Falk; Hyewon Hyun; Sharmila Dorbala
Journal:  J Nucl Med       Date:  2019-04-06       Impact factor: 10.057

5.  Effect of tetracyclines on the dynamics of formation and destructuration of beta2-microglobulin amyloid fibrils.

Authors:  Sofia Giorgetti; Sara Raimondi; Katiuscia Pagano; Annalisa Relini; Monica Bucciantini; Alessandra Corazza; Federico Fogolari; Luca Codutti; Mario Salmona; Palma Mangione; Lino Colombo; Ada De Luigi; Riccardo Porcari; Alessandra Gliozzi; Massimo Stefani; Gennaro Esposito; Vittorio Bellotti; Monica Stoppini
Journal:  J Biol Chem       Date:  2010-11-10       Impact factor: 5.157

6.  Influence of the valine zipper region on the structure and aggregation of the basic leucine zipper (bZIP) domain of activating transcription factor 5 (ATF5).

Authors:  Natalie A Ciaccio; T Steele Reynolds; C Russell Middaugh; Jennifer S Laurence
Journal:  Mol Pharm       Date:  2012-10-23       Impact factor: 4.939

7.  Tracheobronchial amyloidosis: A case report and review of the literature.

Authors:  Andrew C Birkeland; Jonathan B McHugh; Matthew E Spector
Journal:  J Case Rep Med       Date:  2014

8.  Incidence and survival in non-hereditary amyloidosis in Sweden.

Authors:  Kari Hemminki; Xinjun Li; Asta Försti; Jan Sundquist; Kristina Sundquist
Journal:  BMC Public Health       Date:  2012-11-13       Impact factor: 3.295

9.  Pharmacoperone identification for therapeutic rescue of misfolded mutant proteins.

Authors:  P Michael Conn; Jo Ann Janovick
Journal:  Front Endocrinol (Lausanne)       Date:  2011-03-03       Impact factor: 5.555

Review 10.  Effect of nanoparticles on protein folding and fibrillogenesis.

Authors:  Li Fei; Sarah Perrett
Journal:  Int J Mol Sci       Date:  2009-02-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.